7 years on, lorlatinib continues to deliver durable disease control in ALK-positive hashtag#NSCLC. At hashtag#ASCO26, Prof Tony Mok reviews data showing sustained PFS and intracranial protection, reinforcing lorlatinib as a highly effective first-line treatment option. ▶️ ecancer.org/en/video/129...
Prof Tony Mok speaks to ecancer about the long-term follow-up from the phase 3 CROWN trial. It shows that lorlatinib continues to provide exceptional and durabl
